About Elicio Therapeutics, Inc.
https://elicio.comElicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers.
CEO
Robert T. Connelly
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-06-02 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
KNOLL CAPITAL MANAGEMENT, LLC
Shares:630.91K
Value:$5.07M
VANGUARD GROUP INC
Shares:473.86K
Value:$3.81M
BALYASNY ASSET MANAGEMENT L.P.
Shares:148.08K
Value:$1.19M
Summary
Showing Top 3 of 31
About Elicio Therapeutics, Inc.
https://elicio.comElicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $7.76M ▼ | $-10.08M ▲ | 0% | $-0.6 ▲ | $-9.37M ▲ |
| Q2-2025 | $0 | $10.09M ▼ | $-10.56M ▲ | 0% | $-0.66 ▲ | $-10.09M ▲ |
| Q1-2025 | $0 | $10.46M ▼ | $-11.21M ▲ | 0% | $-0.87 ▲ | $-10.76M ▲ |
| Q4-2024 | $0 | $13.17M ▲ | $-14M ▲ | 0% | $-1.15 ▲ | $-13.46M ▲ |
| Q3-2024 | $0 | $10.05M | $-18.84M | 0% | $-1.39 | $-18.41M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $20.61M ▼ | $28.28M ▼ | $24.47M ▼ | $3.82M ▲ |
| Q2-2025 | $22.09M ▲ | $29.53M ▲ | $27.69M ▲ | $1.83M ▼ |
| Q1-2025 | $18.35M ▲ | $28.14M ▼ | $19.24M ▼ | $8.9M ▲ |
| Q4-2024 | $17.62M ▼ | $28.18M ▼ | $39.49M ▼ | $-11.31M ▲ |
| Q3-2024 | $26.02M | $38.39M | $57.37M | $-18.99M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-10.08M ▲ | $-11.09M ▼ | $0 | $9.57M ▼ | $-1.48M ▼ | $-11.09M ▼ |
| Q2-2025 | $-10.56M ▲ | $-8.95M ▲ | $0 | $11.93M ▲ | $3.06M ▲ | $-8.95M ▲ |
| Q1-2025 | $-11.21M ▲ | $-10.12M ▼ | $0 ▲ | $10.33M ▲ | $240K ▲ | $-10.12M ▼ |
| Q4-2024 | $-14M ▲ | $-8.74M ▼ | $-45K ▼ | $227K ▼ | $-8.54M ▼ | $-8.79M ▼ |
| Q3-2024 | $-18.84M | $-7.27M | $0 | $30.75M | $23.52M | $-7.27M |
CEO
Robert T. Connelly
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-06-02 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
KNOLL CAPITAL MANAGEMENT, LLC
Shares:630.91K
Value:$5.07M
VANGUARD GROUP INC
Shares:473.86K
Value:$3.81M
BALYASNY ASSET MANAGEMENT L.P.
Shares:148.08K
Value:$1.19M
Summary
Showing Top 3 of 31